Showing 2,981 - 3,000 results of 3,491 for search '"stem cells"', query time: 0.10s Refine Results
  1. 2981

    AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy by Prakash Vishnu, David M. Aboulafia

    Published 2012-01-01
    “…Clinical trials investigating the role of allogeneic hematopoietic stem cell transplant in ARL are currently underway.…”
    Get full text
    Article
  2. 2982

    Cellular Plasticity in Prostate Cancer Bone Metastasis by Dima Y. Jadaan, Mutaz M. Jadaan, John P. McCabe

    Published 2015-01-01
    “…An electronic search was performed using PubMed for studies that have examined the differential expression of epithelial, mesenchymal, and stem cell markers in human PC bone metastasis tissues. …”
    Get full text
    Article
  3. 2983
  4. 2984

    A 58-Year-Old Female with Progressive Cough and Right Shoulder Pain by Sanket R. Thakore, Faisal A. Khasawneh

    Published 2016-01-01
    “…Establishing accurate diagnosis and starting effective antibiotics are essential steps towards improving outcome. A 58-year-old stem cell transplant patient was admitted to the hospital with necrotizing pneumonia caused by nocardia. …”
    Get full text
    Article
  5. 2985
  6. 2986
  7. 2987
  8. 2988

    Apoptotic Vesicles Attenuate Acute Lung Injury via CD73-Mediated Inhibition of Platelet Activation and NETosis by Tan L, Zhang C, Kou X, Zhao L, Wu D, Li J, Yu C, Xu T, Gao L, Mao X, Zhao C

    Published 2025-01-01
    “…To date, no pharmacological treatment has proven effective for ARDS. Mesenchymal stem cell-derived apoptotic vesicles (apoVs) were recently found to have excellent therapeutic potential for inflammatory diseases. …”
    Get full text
    Article
  9. 2989
  10. 2990
  11. 2991

    Diagnosis and Management of Atypical Chronic Myeloid Leukemia with a t(2;13)(q33;q12) Translocation by John S. Wang, Omar Elghawy, Brett R. Kurpiel, Michael G. Douvas

    Published 2022-01-01
    “…Allogeneic hematopoietic stem cell transplant is likely the preferred treatment, but this can be limited by patient psychosocial support, age, concomitant medical conditions, and availability of an appropriate donor. …”
    Get full text
    Article
  12. 2992

    Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma by Hung-Bo Wu, Shyh-An Yeh, Huei-Yung Chen

    Published 2013-01-01
    “…With intensive salvage chemotherapy and autologous stem cell transplantation, the long-term remission rate for these patients was only 30%, but more selective treatments with higher therapeutic index are needed. …”
    Get full text
    Article
  13. 2993

    Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III... by Roger Owen, John Jones, David Meads, David A Cairns, Christopher Parrish, Gordon Cook, Neil Rabin, Matthew Jenner, Martin Kaiser, Kevin Boyd, Graham Jackson, Catherine Olivier, Amy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Jennifer Bird, Stella Bowcock, Ruth de Tute, Hayley Gardner, Bryony Dawkins, Rowena Henderson, Phillip Best, Bhuvan Kishore, Mark Drayson

    Published 2022-06-01
    “…However, this is less apparent in older, less fit patients, who are ineligible for stem cell transplant. Research is required in this patient group, taking into account frailty and aiming to improve: treatment tolerability, clinical outcomes and quality of life.Methods and analysis Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma is a national, phase III, multicentre, randomised controlled trial comparing standard (reactive) and frailty-adjusted (adaptive) induction therapy delivery with ixazomib, lenalidomide and dexamethasone (IRD), and to compare maintenance lenalidomide to lenalidomide+ixazomib, in patients with newly diagnosed multiple myeloma not suitable for stem cell transplant. …”
    Get full text
    Article
  14. 2994
  15. 2995

    Synthetic embryology of the human heart by Maria Belen Paredes-Espinosa, Janet L. Paluh

    Published 2025-01-01
    “…The evolution of stem cell-based heart models from cells and tissues to organoids and assembloids and recently synthetic embryology gastruloids, is poised to revolutionize our understanding of cardiac development, congenital to adult diseases, and patient customized therapies. …”
    Get full text
    Article
  16. 2996
  17. 2997

    Novel approaches in myelofibrosis by Steffen Koschmieder

    Published 2024-12-01
    “…Currently, the management of MF patients is tailored according to risk scores, with higher‐risk (intermediate‐2 and high‐risk) patients being assessed for allogeneic stem cell transplantation, which remains the only potentially curative treatment option. …”
    Get full text
    Article
  18. 2998

    The Burden of Cost in Bronchiolitis Obliterans Syndrome: Predictions for the Next Decade by Christopher A. Jones, David G. Chapman, Peter Weimersheimer, Luca Fernandez, Oscar Alejandro Mesa, Christian Peters, Bart M. Vanaudenaerde, Mitchell C. Norotsky, Robin Vos

    Published 2016-06-01
    “…The most common life-threatening complication of lung and hematopoietic stem-cell transplantation (HSCT) is bronchiolitis obliterans syndrome (BOS). …”
    Get full text
    Article
  19. 2999
  20. 3000